3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
17
Melanoma
3
Glioma
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Multiple Endocrine Neoplasia Type 1
2
Diffuse Intrinsic Pontine Glioma
2
Thymus Neoplasms
1
Teratoma
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Rhabdoid Tumor
1
Osteitis Deformans
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Mesothelioma
1
Medulloblastoma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Glioblastoma
1
Familial ependymoma
1
Fallopian Tube Neoplasms
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Cystadenocarcinoma, Serous
1
Carcinoma, Hepatocellular
1
Interventions
Pemetrexed
12
Cisplatin
11
pembrolizumab
8
Carboplatin
6
Ipilimumab
5
Nivolumab
4
LMB-100
4
durvalumab
3
Gemcitabine
3
tremelimumab
2
tazemetostat
2
anetumab ravtansine
2
Vinorelbine
2
Plicamycin
2
Dexamethasone
2
Cyclophosphamide
2
Bevacizumab
2
vandetanib
1
tocilizumab
1
spartalizumab
1
ribociclib
1
rebastinib
1
pevonedistat
1
olaparib
1
niraparib
1
nintedanib
1
fludarabine phosphate
1
fludarabine
1
epacadostat
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Mesothelioma
×
ribociclib
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts